Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Rises By 33.3%

PolyPid Ltd. (NASDAQ:PYPD) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 9,200 shares, a growth of 33.3% from the February 13th total of 6,900 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 29,000 shares, the short-interest ratio is currently 0.3 days.

Institutional Investors Weigh In On PolyPid

Large investors have recently added to or reduced their stakes in the business. J. Goldman & Co LP purchased a new stake in shares of PolyPid in the fourth quarter valued at about $391,000. Rosalind Advisors Inc. increased its stake in shares of PolyPid by 49.9% during the 4th quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock worth $3,095,000 after purchasing an additional 338,853 shares in the last quarter. AIGH Capital Management LLC raised its position in shares of PolyPid by 21.8% during the 4th quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock worth $2,509,000 after purchasing an additional 148,199 shares during the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in PolyPid in the 3rd quarter valued at approximately $476,000. 26.47% of the stock is owned by institutional investors and hedge funds.

PolyPid Price Performance

Shares of PYPD traded down $0.13 on Tuesday, reaching $2.94. The stock had a trading volume of 13,011 shares, compared to its average volume of 13,280. PolyPid has a twelve month low of $2.37 and a twelve month high of $5.50. The firm has a market capitalization of $29.96 million, a PE ratio of -0.59 and a beta of 1.27. The firm has a 50-day moving average of $3.02 and a 200 day moving average of $3.22. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.08.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.23). Sell-side analysts expect that PolyPid will post -1.79 EPS for the current year.

Analyst Upgrades and Downgrades

PYPD has been the subject of a number of analyst reports. Rodman & Renshaw initiated coverage on PolyPid in a research note on Tuesday, January 28th. They set a “buy” rating and a $13.00 target price for the company. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, HC Wainwright decreased their target price on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, December 26th.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.